Trinity Biotech, the Nasdaq-listed biotechnology group, has produced strong results for the third quarter to September 30th. After-tax profit rose 71 per cent to more than $1.2 million (£880,000) compared to more than $700,000 for the same period last year. Earnings per share were 54 per cent higher at 4.3 cents per share. Revenue was up by 13 per cent to more than $6.6 million (£4.8 million).

For the nine-month period, after-tax profit rose by 88 per cent to more than $3.2 million (£2.3 million) and earnings per share rose by 63 per cent to 11.4 cents. Revenues were up 15 per cent to $19.5 million (£14.4 million).